ACADIA Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26, 2009

SAN DIEGO—(BUSINESS WIRE)—Oct. 20, 2009—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyutilizing innovative technology to fuel drug discovery and clinicaldevelopment of novel treatments for central nervous system disorders,today announced that it will present at the BIOCOM Investor Conference2009 on Monday, October 26, 2009 at 2:30 p.m. Pacific Time at the HyattRegency in San Diego.

A live webcast of ACADIA’s presentation will be accessible on thecompany’s website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through November 9, 2009.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA’s product candidates includepimavanserin in Phase III for Parkinson’s disease psychosis incollaboration with Biovail, a product candidate in Phase II for chronicpain and a product candidate in Phase I for glaucoma, both incollaboration with Allergan, and AM-831 in IND-track development incollaboration with Meiji Seika Kaisha. All of the product candidates inACADIA’s pipeline emanate from discoveries made using its proprietarydrug discovery platform. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, VicePresident and Chief Financial Officer
858-558-2871